Atypical and Malignant Meningiomas

Textbook of Uncommon Cancer, Third Edition

Volumn , Issue , 2006, Pages 639-648

  Kaba, Samer E ^a   Kyritsis, Athanassios P ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atypical; Chemotherapy; Malignant; Meningioma; Radiotherapy; Surgery

Indexed keywords

EID: 84889284150     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470030542.ch58     Document Type: Chapter

References (133)

1. Lantos PL, Vandenberg SR, Kleihues P. Tumors of the nervous system. In Graham DI, Lantos PL (eds) Greenfield's Neuropathology, 6th ed. London: Arnold, 1997: 583.
2. Central Brain Tumor Registry of the United States. CBTRUS First Annual Report, Chicago, IL, 1995.
3. Longstreth WT Jr, et al. Epidemiology of intracranial meningioma. Cancer 1993; 72: 639.
4. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986; 25: 233.
5. Mahmood A, et al. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 1993; 33: 955.
6. Bolger GB, et al. Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma. N Engl J Med 1985; 312: 564.
7. Rubinstein AB, et al. Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 1994; 81: 184.
8. Carroll RS, et al. Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery 1995; 37: 92.
9. Brandis A, et al. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 1993; 33: 212.
10. Poulsgard L, Schroder HD, Ronne M. Cytogenetic studies of 11 meningiomas and their clinical significance. II. Anticancer Res 1990; 10: 535.
11. Koehorst SG, et al. Detection of an oestrogen receptor-like protein in human meningiomas by band shift assay using a synthetic oestrogen responsive element (ERE). Br J Cancer 1993; 68: 290.
12. Koehorst SG, et al. Estrogen receptor variants mRNA in human meningiomas. Ann N Y Acad Sci 1993; 684: 222.
13. Carroll RS, et al. Androgen receptor expression in meningiomas. J Neurosurg 1995; 82: 453.
14. Maxwell M, et al. Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 1993; 78: 456.
15. Reubi JC, et al. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989; 134: 337.
16. Westphal M, Herrmann HD. Epidermal growth factor-receptors on cultured human meningioma cells. Acta Neurochir 1986; 83: 62.
17. Weisman AS, Raguet SS, Kelly PA. Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 1987; 47: 2172.
18. Weisman AS, Villemure JG, Kelly PA. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas. Cancer Res 1986; 46: 2545.
19. Vagner-Capodano AM, et al. Correlation between cytogenetic and histopathological findings in 75 human meningiomas. Neurosurgery 1993; 32: 892.
20. Rempel SA, et al. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993; 53: 2386.
21. Sulman EP, White PS, Brodeur GM. Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene 2004; 23: 1014-20.
22. Maxwell M, et al. Human meningiomas co-express Platelet-derived Growth Factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990; 46: 16.
23. Adams EF, et al. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules. Int J Cancer 1991; 49: 398.
24. Todo T, Adams EF, Fahlbusch R. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J Neurosurg 1993; 78: 463.
25. Takahashi JA, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Nat Acad Sci USA 1990; 87: 5710.
26. Jensen RL, et al. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 1995; 36: 365.
27. Kitagawa N, et al. Expression of a functional endothelin (ETA) receptor in human meningiomas. J Neurosurg 1994; 80: 723.
28. Carroll RS, et al. Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas. Neurosurgery 1996; 38: 367.
29. Kono S, et al. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 256.
30. Hoshino T, et al. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 1986; 38: 369.
31. Miyagami M, et al. Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies. No to Shinkei 1996; 48: 39.
32. Cobb MA, et al. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. J Neurosurg 1996; 84: 85.
33. Ludwin SK, Rubinstein LJ, Russell DS. Papillary meningioma: a malignant variant of meningioma. Cancer 1975; 36: 1363.
34. Pasquier B, et al. Papillary meningioma. Clinicopathologic study of seven cases and review of the literature. Cancer 1986; 58: 299.
35. Modan B, et al. Radiation-induced head and neck tumours. Lancet 1974; 1: 277.
36. Mack EE, Wilson CB. Meningiomas induced by high-dose cranial radiation. J Neurosurg 1993; 79: 28.
37. Ghim TT, et al. Childhood intracranial meningiomas after high-dose irradiation. Cancer 1993; 71: 4091.
38. Preston-Martin S, et al. Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst 1980; 65: 67.
39. Choi NW, Schuman LM, Gullen WH. Epidemiology of primary central nervous system neoplasms. II. Case-control study. Am J Epidemiol 1970; 91: 467.
40. Annegers JF, et al. Head trauma and subsequent brain tumors. Neurosurgery 1979; 4: 203.
41. Poulsgard L, Ronne M, Schroder HD. Cytogenetic studies of 19 meningiomas and their clinical significance. I. Anticancer Res 1989; 9: 109.
42. Menon AG, et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 1997; 14: 611.
43. Al Saadi A, et al. Cytogenetic studies of human brain tumors and their clinical significance. II. Meningioma. Cancer Genet Cytogenet 1987; 26: 127.
44. Rey JA, et al. Incidence and origin of dicentric chromosomes in cultured meningiomas. Cancer Genet Cytogenet 1988; 35: 55.
45. Rey JA, et al. Chromosomal involvement secondary to-22 in human meningiomas. Cancer Genet Cytogenet 1988; 33: 275.
46. Bello MJ, et al. Chromosome 22 heterozygosity is retained in most hyperdiploid and pseudodiploid meningiomas. Cancer Genet Cytogenet 1993; 66: 117.
47. Lomas J, et al. Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 2004; 148: 148-51.
48. Mihaila D, et al. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 2003; 9: 4443-51.
49. Rajcan-Separovic E, et al. Loss of 1p and 7p in radiation-induced meningiomas identified by comparative genomic hybridization. Cancer Genet Cytogenet 2003; 144: 6-11.
50. Dumanski JP, et al. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Nat Acad Sci USA 1987; 84: 9275.
51. Seizinger BR, et al. Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Nat Acad Sci USA 1987; 84: 5419.
52. Collins VP, Nordenskjold M, Dumanski JP. The molecular genetics of meningiomas. Brain Pathol 1990; 1: 19.
53. Pulst SM, et al. Familial meningioma is not allelic to neurofibromatosis 2. Neurology 1993; 43: 2096.
54. Gutmann DH, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000; 9: 1495-500.
55. Carstens C, et al. Human KRAS oncogene expression in meningioma. Cancer Lett 1988; 43: 37.
56. Smidt M, Kirsch I, Ratner L. Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. J Clin Invest 1990; 86: 1151.
57. Kazumoto K, et al. Enhanced expression of the sis and c-myc oncogenes in human meningiomas. J Neurosurg 1990; 72: 786.
58. Mashiyama S, et al. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991; 6: 1313.
59. Wang JL, et al. Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 1995; 64: 223.
60. Amatya VJ, Takeshima Y, Inai K. Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 2004; 17: 705-10.
61. Lusis E, Gutmann D. Meningioma: an update. Curr Opin Neurol 2004; 17: 687-92.
62. Rohringer M, et al. Incidence and clinicopathological features of meningioma. J Neurosurg 1989; 71: 665.
63. DeMonte F, al-Mefty O. Meningiomas. In Kaye AH, Laws ER (eds) Brain Tumors. New York: Churchill Livingstone, 1995: 675.
64. Younis GA, et al. Aggressive meningeal tumors: review of a series. J Neurosurg 1995; 82: 17.
65. Kremer S, et al. Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma. Neuroradiology 2004; 46(8): 642-8.
66. Nyberg G, et al. PET-methionine of skull base neuromas and meningiomas. Acta Otolaryngol 1997; 117: 482.
67. Di Chiro G, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987; 164: 521.
68. Cremerius U, et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med 1997; 38: 26.
69. Lippitz B, et al. PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochir Suppl 1996; 65: 108.
70. Shioya H, et al. Longitudinal analysis of glucose metabolism in recurrent meningioma. No to Shinkei 1994; 46: 1088.
71. Kinuya K, et al. Thallium-201 brain SPECT to diagnose aggressiveness of meningiomas. Ann Nucl Med 2003; 17(6): 463-7.
72. Philippon J, Cornu P. The recurrence of meningiomas. In al-Mefty O (ed) Meningiomas. New York: Raven Press, 1991: 87.
73. Palma L, et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997; 86: 793.
74. Mirimanoff RO, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985; 62: 18.
75. Thomas HG, Dolman CL, Berry K. Malignant meningioma: clinical and pathological features. J Neurosurg 1981; 55: 929.
76. Stoller JK, et al. Intracranial meningiomas metastatic to the lung. Cleve Clin J Med 1987; 54: 521.
77. Goldsmith BJ, et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990 [published erratum appears in J Neurosurg 1994: 80(4):777]. J Neurosurg 1994; 80: 195.
78. Barbaro NM, et al. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 1987; 20: 525.
79. Forbes AR, Goldberg ID. Radiation therapy in the treatment of meningioma: the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 1984; 2: 1139.
80. Milosevic MF, et al. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 1996; 34: 817.
81. Shimizu T, Iijima M, Tanaka Y. Radiotherapy for intracranial meningioma: special reference to malignant and high risk benign meningioma. Nippon Igaku Hoshaen Gakkai Zasshi 1995; 55: 1047.
82. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996; 84: 753.
83. Lunsford DL. Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J Neurosurg 1994; 80: 187-90.
84. Taut FJ, Zeller WJ. In vitro chemotherapy of steroid receptor positive human meningioma low-passage primary cultures with nitrosoureamethionine-steroid conjugates. Clin Neuropharmacol 1996; 19: 520.
85. Tsuchida T, et al. Chemosensitivity of cultured meningiomas. Hum Cell 1995; 8: 155.
86. Russell T, Moss T. Metastasizing meningioma. Neurosurgery 1986; 19: 1028.
87. Philippon J, et al. Recurrent meningioma. Neurochirurgie 1986; 32(Suppl 1): 1.
88. LeMay DR, Bucci MN, Farhat SM. Malignant transformation of recurrent meningioma with pulmonary metastases. Surg Neurol 1989; 31: 365.
89. Hoshino T, et al. Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine. Cancer 1986; 58: 1466.
90. Cho KG, et al. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling. J Neurosurg 1986; 65: 790.
91. Shibuya M, et al. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling. Neurosurgery 1992; 30: 494.
92. Suwa T, et al. Invasive meningioma: a tumor with high proliferating and 'recurrence' potential. Acta Neurochir 1995; 136: 127.
93. Colvett KT, et al. High PCNA index in meningiomas resistant to radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38: 463.
94. Kaba SE, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2b. Neurosurgery 1997; 40: 271.
95. Boker DK, Meurer H, Gullotta F. Recurring intracranial meningiomas. Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 1985; 29: 11.
96. Kondziolka D, et al. Gamma knife radiosurgery of meningiomas. Stereotact Funct Neurosurg 1991; 57: 11.
97. Kondziolka D, et al. Stereotactic radiosurgery of meningiomas. J Neurosurg 1991; 74: 552.
98. Kumar PP, et al. Brachytherapy: a viable alternative in the management of basal meningiomas. Neurosurgery 1991; 29: 676.
99. Vuorinen V, et al. Interstitial radiotherapy of 25 parasellar/clival meningiomas and 19 meningiomas in the elderly. Analysis of shortterm tolerance and responses. Acta Neurochir 1996; 138: 495.
100. Gutin PH, et al. Brachytherapy of recurrent tumors of the skull base and spine with iodine-125 sources. Neurosurgery 1987; 20: 938.
101. Stewart DJ, et al. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. JNO 1995; 24: 189.
102. Bernstein M, et al. Necrosis in a meningioma following systemic chemotherapy. Case report. J Neuro-surg 1994; 81: 284.
103. Kyritsis AP. Chemotherapy for meningiomas. JNO 1996; 29: 269.
104. Schrell UM, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 1997; 86: 845.
105. Schrell UM, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997; 86: 840.
106. Mason WP, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002; 97: 341-6.
107. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2000; 49: 165-70.
108. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004; 62: 1210-2.
109. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994; 9(Suppl 1): 202.
110. Grunberg SM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74: 861.
111. Lamberts SW, et al. Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992; 55: 486.
112. Goodwin JW, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. JNO 1993; 15: 75.
113. Koper JW, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991; 27: 416.
114. Bergstrom M, et al. Modulation of tumor metabolism using hormonally acting drugs in patients with meningioma. J Endocrinol Invest 1989; 12(Suppl 2): 91.
115. Li VW, et al. Microvessel count and cerebral fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994; 344: 82.
116. Folkman J, Klagsburn M. Angiogenic factors. Science 1987; 235: 442.
117. Wober-Bingol C, et al. Interferon-alfa-2b for meningioma. Lancet 1995; 345: 331.
118. Muhr C, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001; 7(8): 2269-76.
119. Salcman M. Malignant meningiomas. In al-Mefty O (ed) Meningiomas. New York: Raven Press, 1991: 75.
120. Kleinschmidt-DeMasters BK, Avakian JJ. Wallenberg syndrome caused by CSF metastasis from malignant intraventricular meningioma. Clin Neuropathol 1985; 4: 214.
121. Som PM, et al. 'Benign' metastasizing meningiomas. Am J Neuroradiol 1987; 8: 127.
122. Miller DC, et al. Benign metastasizing meningioma. Case report. J Neurosurg 1985; 62: 763.
123. Fukushima T, et al. Papillary meningioma with pulmonary metastasis. Case report. J Neurosurg 1989; 70: 478.
124. Wasserkrug R, Peyser E, Lichtig C. Extracranial bone metastases from intracranial meningiomas. Surg Neurol 1979; 12: 480.
125. Guthrie BL. Meningeal hemangiopericytomas. In Kaye AH, Laws ER (eds) Brain Tumors. New York: Churchill Livingstone, 1995: 705.
126. Begg CF, Garret R. Hemangiopericytoma occurring in the meninges. Cancer 1954; 7: 602.
127. Guthrie BL, et al. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 1989; 25: 514.
128. Schroder R, Firsching R, Kochanek S. Hemangiopericytoma of meninges. II. General and clinical data. Zentralbl Neurochir 1986; 47: 191.
129. Fukui M, et al. Irradiated meningiomas: a clinical evaluation. Acta Neurochir 1980; 54: 33.
130. Bastin KT, Mehta MP. Meningeal hemangiopericytoma: defining the role for radiation therapy. JNO 1992; 14: 277.
131. Borg MF, Benjamin CS. Haemangiopericytoma of the central nervous system. Australas Radiol 1995; 39: 36.
132. Staples JJ, et al. Hemangiopericytoma-the role of radiotherapy. Int J Radiat Oncol Biol Phys 1990; 19: 445.
133. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20: 22.